Q4 2025 · 13F-HR
Sofinnova Investments, Inc.holdings as filed
Filed 2026-02-13 · accession 0001104659-26-015127
$2.32B
Reported value
60
Positions
2025-12-31
Period end
The Brief · Sofinnova Investments, Inc. · Q4 2025
AI · grounded in 13F
Sofinnova Investments, Inc. closed its position in Gilead Sciences Inc GILD, reducing exposure by $139M. The fund established new positions in Bristol-Myers Squibb Co BMY for $81.6M and Eli Lilly & Co LLY for $66.3M. Additionally, the fund accumulated shares of AstraZeneca PLC AZNN by 98.1% and Jazz Pharmaceuticals PLC JAZZ by 63%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $355.2M | 15.3% | 1,550,280 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $163.2M | 7.04% | 959,860 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $150.1M | 6.47% | 1,632,334 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $141.5M | 6.10% | 2,793,987 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $81.6M | 3.52% | 1,512,994 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $76.8M | 3.31% | 157,641 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $74.6M | 3.22% | 164,594 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $72.6M | 3.13% | 317,783 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $71.9M | 3.10% | 126,968 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $70.1M | 3.02% | 1,973,625 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $66.3M | 2.86% | 61,652 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $57.8M | 2.49% | 1,904,408 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $55.1M | 2.38% | 720,448 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $53.7M | 2.32% | 745,116 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $44.1M | 1.90% | 2,254,161 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $41.4M | 1.79% | 697,133 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $40.4M | 1.74% | 534,845 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $39.8M | 1.72% | 180,265 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES INC | $37.1M | 1.60% | 125,722 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $36.1M | 1.56% | 3,435,542 | Common | SOLE |
| 45720N103 | INBX | INHIBRX BIOSCIENCES INC | $35.9M | 1.55% | 454,657 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $34.8M | 1.50% | 1,618,477 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $34.1M | 1.47% | 1,696,752 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $32.5M | 1.40% | 288,128 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $30.6M | 1.32% | 885,121 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $30.3M | 1.31% | 2,293,788 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $29.9M | 1.29% | 299,417 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $29.1M | 1.25% | 271,394 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $27.6M | 1.19% | 1,104,274 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $27.5M | 1.19% | 553,095 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $27.3M | 1.18% | 156,801 | Common | SOLE |
| H01301128 | ALC | ALCON AG | $26.2M | 1.13% | 332,520 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $26.1M | 1.13% | 1,096,705 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $25.1M | 1.08% | 378,219 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $20.7M | 0.89% | 745,169 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $18.5M | 0.80% | 438,630 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $18.1M | 0.78% | 3,365,446 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $15.9M | 0.69% | 734,582 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $13.9M | 0.60% | 287,690 | Common | SOLE |
| 36266G107 | GEHC | GE HEALTHCARE TECHNOLOGIES I | $13.2M | 0.57% | 160,876 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $10.9M | 0.47% | 437,819 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $10.3M | 0.44% | 101,443 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $8.8M | 0.38% | 111,010 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.4M | 0.27% | 527,099 | Common | SOLE |
| 574795100 | MASI | MASIMO CORP | $6.0M | 0.26% | 46,201 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $4.2M | 0.18% | 176,513 | Common | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $3.2M | 0.14% | 222,654 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $2.7M | 0.12% | 158,182 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $2.7M | 0.12% | 59,900 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $2.6M | 0.11% | 153,320 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $2.2M | 0.10% | 12,266 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $2.1M | 0.09% | 28,366 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $1.9M | 0.08% | 83,300 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $1.8M | 0.08% | 304,770 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $1.8M | 0.08% | 23,100 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $1.8M | 0.08% | 65,567 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $1.7M | 0.07% | 107,391 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $753,058 | 0.03% | 137,721 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $574,768 | 0.02% | 12,414 | Common | SOLE |
| 45175G207 | IMA | IMAGENEBIO INC | $220,000 | 0.01% | 31,884 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.